Horizon buys Crealta Holdings for $510M
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
Pharmaceuticals, Biotechnology and Life Sciences
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.
Johnson & Johnson has completed the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
Genomic Vision – has signed a strategic partnership with the University-Hospital Institute (IHU) Imagine, the largest European genetic research and care cluster.
TxCell SA has signed a 5-year agreement with MaSTherCell, a Contract Manufacturing Organization (CMO), based in Belgium.
According to this agreement, MaSTherCell will be the exclusive manufacturer in Europe of all products from TxCell’s ASTrIA platform.
Sun Pharmaceutical Industries, largest India-based generic pharmaceutical companies, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Novartis’ Gleevec.
Anavex has appointed Ulrich Elben, PhD as Vice President of Preclinical Operations, who will be responsible for the pipeline development and optimization.
Premaitha Health said Wednesday that Adgenix has already signed up its first laboratory customer for Premaitha in France, with a signed contract for a minimum of three years to supply LaboSud with the Iona test.
Flood in India’s Chennai suspends operations at Natco Pharma API plant